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The objective of this study was to evaluate the role of cytokines in hepatic fibrosis in the prehepatosplenic
and early hepatosplenic stages of schistosomiasis mansoni. Hepatic fibrosis was classified by ultrasonography
of 94 patients. Immunological evaluation was performed by the measurement of secreted cytokines (interleu-
kin-5 [IL-5], IL-10, IL-13, gamma interferon, tumor necrosis factor alpha, and transforming growth factor )
in peripheral blood mononuclear cells (PBMC) stimulated by Schistosoma mansoni antigens. Significantly,
higher levels of IL-5, IL-10, and IL-13 were found in supernatants of soluble egg antigen-stimulated PBMC
from subjects with degree III hepatic fibrosis compared to patients with degree I or II fibrosis. Significant
increases in IL-5 and IL-13 levels were also observed in some of the subjects who remained untreated for 1 year
following initial assessment and developed more serious fibrosis during this period. The data suggest a role for
type 2 cytokines in hepatic fibrosis in human schistosomiasis mansoni.
Schistosomiasis is a chronic and debilitating disease that
affects over 200 million people worldwide (17). The pathology
resulting from infection with the helminth parasite Schisto-
soma mansoni is predominantly caused by the host immune
response to parasite eggs that are laid in the portal venous
system and then become trapped in hepatic sinusoids and
sequestered within granulomatous lesions (3, 8, 9, 22, 27). The
fibrosis associated with granuloma formation can lead to portal
hypertension, which causes much of the morbidity and mortal-
ity associated with schistosomiasis (14).
The formation of granulomas around schistosome eggs is
mediated by CD4 T cells (28), and more recent studies have
furnished numerous insights into the cytokine cascade that
controls the development of these lesions (6, 8, 9, 18). In the
murine model of schistosomiasis, type 2-associated cytokines,
including interleukin-4 (IL-4), IL-5, and IL-13, contribute to
granuloma formation and the presence of eosinophils in these
lesions (9). However, in human schistosomiasis, studies have
shown that high levels of tumor necrosis factor alpha (TNF-)
produced by peripheral blood mononuclear cells (PBMC)
stimulated with schistosome antigen (Ag) are significantly as-
sociated with the presence of hepatosplenomegaly (4, 16, 19),
while gamma interferon (IFN-) has a protective effect in
severe fibrosis of the liver (4, 16). As hepatoesplenic disease is
a long-term complication of schistosomiasis mansoni and is
considered to be indicative of severe hepatic and periportal
fibrosis, it is conceivable that the immune mechanisms respon-
sible for this lesion occur much earlier during infection and
precede the downstream development of hepatosplenomegaly.
Consequently, it is important to evaluate the immune response
in the early events of hepatic fibrosis. The present study mea-
sured the cytokine profiles in supernatants of soluble egg Ag-
stimulated PBMC from schistosomiasis patients with different
stages of hepatic fibrosis, and an association between type 2
cytokine production and progression to fibrosis was detected.
MATERIALS AND METHODS
Endemic area and subject selection. This study included 94 patients with
schistosomiasis; for each patient the degree of fibrosis was determined by ultra-
sonography. The majority of the patients (n  79) were selected from Caatinga
do Moura, a village where schistosomiasis mansoni is endemic, located 380 km
from Salvador, the capital of the state of Bahia. Agriculture is the main economy
of the village, and domestic use of the water contributes to constant aquatic
exposure in a large part of the population. Because there were few patients with
degree III hepatic fibrosis in Caatinga do Moura, more patients with degree III
fibrosis were recruited from two other areas of schistosomiasis endemicity: Ta-
quarendi (n  9), another village with an agriculture-based economy, located 30
km from Caatinga do Moura, and Maruim (n  6), a village from the state of
Sergipe, north of Bahia state. None of the field sites was an area of endemicity
for malaria, leishmaniasis, or Chagas’ disease, but the sites have other intestinal
parasitic infections such as Ascaris lumbricoides, Trichuris trichiura, Ancylostoma
duodenale, Entamoeba coli, Entamoeba histolytica, and Giardia lamblia. All pa-
tients with degree III hepatic fibrosis had small spleen sizes (1 to 3 cm of the left
costal ribs) and no past digestive bleeding or other signs of severe portal hyper-
tension. They were all compensated forms of hepatosplenic disease that had not
even received previous hospital care.
The inclusion criteria for subjects were as follows: positive Kato-Katz parasi-
tological examinations for schistosomiasis, no history of therapy for schistoso-
miasis in the last 3 years, and hepatic fibrosis as assessed by ultrasonography.
Exclusion criteria included being under 4 or above 60 years of age or having
positive serology for human immunodeficiency virus, human T-cell leukemia
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virus type 1, or hepatitis virus types B and C, as well as other conditions that
could interfere in the immunological evaluation or classification by ultrasonog-
raphy. Clinical and parasitological stool exams were performed in the study
population every 3 years, followed by specific treatment for S. mansoni with
oxaminiquine (20 mg/kg of body weight). All patients or the guardians of minors
signed informed consent statements, and the study was approved by the Ethical
Committee of the Hospital Universita´rio Professor Edgard Santos.
Ultrasonography. Ultrasonographic examination was performed by using
World Health Organization criteria established in 1993 for the classification of
hepatic fibrosis, according to a method described previously (1, 12). This classi-
fication defines hepatic fibrosis as degree 0 if the periportal tract thickness is 3
mm, as degree I if it is 3 to 5 mm thick, as degree II if it is 5 to 7 mm thick, and
as degree III if it is 7 mm thick. The examinations were performed by two
independent persons, and a correlation between periportal thickness and portal
vein diameter and spleen size was demonstrated (12). Twenty-one subjects who
went untreated, even after several attempts to locate them for treatment with
schistosomicidal drugs, were reevaluated by ultrasonographic exam 1 year after
the first evaluation. Nineteen of these patients showed an increase in the peri-
portal tract thickness, but in only 12 had this increase induced a change in the
degree of hepatic fibrosis. For three patients, the fibrosis had changed from
degree 0 to I, and for nine patients, the fibrosis had changed from degree I to II.
One year after treatment with oxaminiquine, all patients had improved and
returned to degree 0 or I of fibrosis (12).
Antigens. The S. mansoni-specific Ags used were soluble extract of whole adult
S. mansoni (SWAP) and soluble egg Ag (SEA), prepared as previously described
(21).
Immunological methods. PBMC were isolated from heparinized blood by
density gradient centrifugation by using Histopaque 1077 (Sigma Diagnostic, St.
Louis, Mo.) as previously described (24). Briefly, 3  106 cells in 1 ml of RPMI
1640 (GIBCO-BRL) medium supplemented with 10% AB Rh-positive sera were
either not stimulated or stimulated with S. mansoni-specific Ags at optimal
concentrations determined previously by testing noninfected controls from Sal-
vador. The Ag concentration of 10 g/ml for both SEA and SWAP was chosen
because it was able to induce a response in PBMC from schistosomiasis patients
but not from the control subjects. After a 72-h incubation at 37°C in 5% CO2, the
supernatants were collected and stored at 	20°C for the later measurement of
the cytokine levels produced by the stimulated PBMC.
Cytokine level determination. Levels of the cytokines (IL-5, IL-10, IFN-,
transforming growth factor 
 [TGF-
], IL-13, and TNF-) were measured in
supernatants from PBMC cultures stimulated with the two S. mansoni Ags.
Cytokine concentrations were determined by using sandwich enzyme-linked im-
munosorbent assays (ELISAs), and the results were expressed as picograms of
cytokine per milliliter of supernatant, based on comparisons with standard
curves, according to a previously described technique (24, 25). Commercial kits
from R&D Systems (Minneapolis, Minn.) were used for IFN-, IL-10, TNF-,
IL-13, and TGF-
. Duo Set antibodies (PharMingen, San Diego, Calif.) were
used to test IL-5. Immulon 2 ELISA plates were from Dynatech. The techniques
described by the manufacturers were followed, except that the diluent for estab-
lishing the standard curves was the same (RPMI plus 10% AB-positive sera) as
for the tested samples. The sensitivity cutoffs for the ELISAs for each of the
cytokines were as follows: 30 pg/ml for IFN-, IL-5, IL-10 and TNF-; 14 pg/ml
for IL-13; and 7 pg/ml for TGF-
. The results considered for analysis were the
differences of cytokine concentrations from the stimulated culture supernatants
versus the supernatants from the nonstimulated PBMC cultures.
Statistical methods. The differences in demographic data, infection levels, and
cytokine levels in PBMC supernatants between the groups of subjects with
degrees I, II, and III hepatic fibrosis were analyzed by the Mann-Whitney test. A
nonparametric test was chosen because the cytokine data did not follow a
Gaussian distribution. The differences in cytokine levels in the group of patients
who increased the degree of fibrosis in two consecutive evaluations were com-
pared by a Wilcoxon signed rank test for matched groups. These statistical
analyses were performed by using the Instat program for Macintosh. An  value
of 5% was considered for significance.
RESULTS
Overview of the subject groups. The 94 schistosomiasis pa-
tients selected for study had an age range of 5 to 55 years, with
a mean and standard deviation (SD) of 16  8 years (46 male
and 48 female subjects). Their infection levels ranged from 24
to 1,784 eggs per gram (EPG) of feces. According to ultra-
sonographic examination, 8 subjects were classified as having
degree 0 hepatic fibrosis, 50 had degree I, 22 had degree II, and
14 had degree III fibrosis. The age, sex, and infection levels
(mean  SD unless otherwise stated) in the subgroups of
patients with different degrees of hepatic fibrosis are described
in Table 1. Patients with degrees 0 and I hepatic fibrosis were
included in the same subgroup. Differences in age were ob-
served between patients with degree 0 to I (16  11.5 years)
and degree  (21  10.5 years) hepatic fibrosis (P  0.01 by
Mann-Whitney test). Differences in infection levels were also
observed between the patients with degrees  and  (379 
426 and 117  98 EPG of feces, respectively) and between
degrees  and  (412  399 and 117  98 EPG of feces,
respectively) hepatic fibrosis (P  0.01 by Mann Whitney test).
The cytokine concentrations in Ag-stimulated PBMC cultures
from schistosomiasis patients were determined. The levels of
the cytokines IFN-, TNF-, IL-10, IL-13, and TGF-
 in SEA-
stimulated PBMC supernatants were compared in schistoso-
miasis subjects with different degrees of hepatic fibrosis. The
differences in the numbers of patients evaluated for each cy-
tokine reflects the limited availability of culture supernatants,
which itself reflects the limited numbers of PBMC obtained.
Based on previous reports, we prioritized the evaluation of
IFN- (n  67), TNF- (n  56), and IL-5 (n  73), leaving
less supernatant for the measurement of IL-10 (n  49), IL-13
(n  39), and TGF-
 (n  41). Because patients were treated
after donating PBMC samples, we were unable to perform
repeat analyses. We were unable to assess IL-4 production due
to the difficulty of measuring this cytokine in PBMC superna-
tants (26).
SEA-induced cytokine responses. A great variability in cyto-
kine levels (given as mean  SD unless otherwise stated) was
observed in general, showing the heterogeneity of the response
to S. mansoni Ags. No significant differences in IFN- levels
were observed in supernatants from SEA-stimulated PBMC
from the three groups of patients (79  295.8, 3  14.2, and 44
 79 pg/ml for patients with degrees I, II, and III fibrosis,
respectively) (Fig. 1A). The levels of TNF- in SEA-stimulated
PBMC supernatants also did not show any differences between
the groups (44  124.2, 37  93.3, and 19  14.8 pg/ml for
TABLE 1. Demographic data and infection intensity for
schistosomiasis study subjects with different dgrees of hepatic
fibrosis as classified by ultrasonography
Characteristic
Value for group with infection level ofa:
Degrees 0
and I Degree II Degree III
No. of subjects
Total 58 22 14
Male/female 31/27 11/11 8/6
Age (yr)
Range 5–55 9–45 7–50
Mean  SD 16  11.5 A 21  10.5 A 21  13.3
No. of eggs/g of
stool
Range 24–1,784 40–1,616 24–216
Mean  SD 379  426 B 412  399 117  98 BC
a The same letter is placed next to combinations for which P  0.01.













patients with degrees I, II, and III fibrosis, respectively) (Fig.
1B).
Levels of IL-5 were significantly lower in supernatants from
SEA-stimulated PBMC of subjects with degrees I (93  248.4
pg/ml) and II (11  29.8 pg/ml) of hepatic fibrosis than in
supernatants from patients with degree III hepatic fibrosis (669
 815.6 pg/ml) (P  0.01 and P  0.009, respectively, by
Mann-Whitney test) (Fig. 2A). IL-13 levels in supernatants of
SEA-stimulated PBMC were also higher in subjects with de-
gree III fibrosis (116  120.9 pg/ml), compared to those with
degrees I (24  11.4 pg/ml) or II (86  166.5 pg/ml) hepatic
fibrosis (P  0.009 and P  0.05, respectively, by Mann-Whit-
ney test) (Fig. 2B). Higher levels of IL-10 were observed in
supernatants of SEA-stimulated PBMC from patients with de-
gree III hepatic fibrosis (187  110 pg/ml) compared to those
with degree I (63  62.9 pg/ml) or II (66  53 pg/ml) hepatic
fibrosis (P 0.01 and P 0.03, respectively, by Mann-Whitney
test) (Fig. 3A). No differences were detected in TGF-
 levels
in SEA-stimulated PBMC supernatants between the groups of
patients with degrees , , and  hepatic fibrosis (28  18.7,
33  40, and 26  16 pg/ml, respectively; P  0.05 by Mann-
Whitney test) (Fig. 3B).
SWAP-induced cytokine responses. High levels of IL-5 were
produced by SWAP-stimulated PBMC from all groups of pa-
tients (1043  1844.5, 1319  1706.7, and 2219  2011 pg/ml
for patients with degrees I, II, and III fibrosis, respectively),
with significantly higher levels in patients with degree III versus
degree I fibrosis (P  0.03 by Mann-Whitney test). A signifi-
cantly (P  0.03 by Mann-Whitney test) higher level of IFN-
was observed in supernatants of SWAP-stimulated PBMC
from patients with degree II (n  23) versus degree I (n  57)
versus degree III (n  14) hepatic fibrosis (257  354 versus
104  189 versus 39  58 pg/ml, respectively). There were no
significant differences (P  0.05) in the levels of TNF- and
IL-10 in cultures stimulated with SWAP (data not shown).
Responses of patients who remained untreated following
initial assessment. Even after an active search, 21 patients
missed treatment that should have been administered at the
end of the study and remained untreated 1 year after their first
ultrasonography examination. Ultrasonography was repeated
on these individuals, and the periportal thickness measure-
ments of 19 (90%) of the patients had increased, while the
periportal thickness measurements of 2 of these patients were
similar to initial measurements. Within this group, 12 of 19
(57%) patients exhibited more severe fibrosis compared to the
previous exam. In three patients the fibrosis index had changed
from degree 0 to degree I, and in nine patients the fibrosis
index had increased from degree I to degree II. Immunological
evaluation was repeated in these patients and compared with
the first evaluation. An increase in the levels of some cytokines
was observed in SEA-stimulated PBMC supernatants. Levels
of IFN- were evaluated in 18 patients, and 2 patients pre-
sented a decrease; the others did not show any significant
change in the second versus first evaluations (Fig. 4A). TNF-
FIG. 1. IFN- () and TNF- () levels in SEA-stimulated PBMC supernatants in schistosomiasis patients with different degrees of hepatic
fibrosis. Differences between the groups were not statistically significant (P  0.05 by Mann Whitney test).
FIG. 2. IL-5 (A) and IL-13 (B) levels in SEA-stimulated PBMC supernatants in schistosomiasis patients with different degrees of hepatic
fibrosis. a, P  0.01; b, P  0.009; c, P  0.0009; d, P  0.05 (Mann-Whitney test).













levels increased in 5 patients and decreased in 2 patients and
remained at similar levels in 8 of the 15 patients tested (Fig.
4B). IL-5 levels increased in 9 patients, decreased in 1 patient,
and remained at similar levels in 8 of the 18 patients tested
(Fig. 5A); IL-13 levels showed a major increase in 5 patients
and a minor increase in 2 patients and decreased or remained
at similar levels in 2 of the 9 patients tested (Fig. 5B). The
levels of IL-5 and IL-13 were significantly higher in the second
evaluation (206  434 and 89.7  56 pg/ml, respectively) in
comparison to the first evaluation (19 62 and 9.6 11 pg/ml,
respectively) (P  0.03 and P  0.04, respectively, by a Wil-
coxon signed rank test). IL-10 levels also increased in 7 of 13
patients, decreased in 3 patients, and remained at similar levels
in 3 other patients (Fig. 6A). TGF-
 levels increased in 6 of 14
patients, decreased in 2 patients, and remained at similar levels
in 2 other patients (Fig. 6B). No statistically significant differ-
ences were observed in the levels of IFN-, TNF-, IL-10, and
TGF-
 in SEA-stimulated PBMC supernatants from the sec-
ond to the first evaluations (P  0.4, P  0.4, P  0.3, and P
 0.4, respectively, by Wilcoxon signed rank test). No signifi-
cant differences were observed between the levels of cytokines
in SWAP-stimulated PBMC supernatants from the second to
the first evaluations.
DISCUSSION
A type 2 cytokine pattern dominates the immune response in
mice and humans chronically infected by S. mansoni. In mice,
IL-4 and IL-13 play a major role in egg granuloma formation,
and IL-13 was shown to play a significant role in the develop-
ment of hepatic fibrosis (8, 9, 10). In humans, although low
IFN- and high TNF- are associated with severe hepatic
fibrosis (4, 16), it is still not clear which cytokines are involved
in the progression of schistosomiasis mansoni pathology. The
present study evaluated the cytokine profile in schistosomiasis
patients developing hepatic fibrosis in prehepatosplenic and
early hepatosplenic stages of the disease and showed an asso-
ciation between a type 2 cytokine profile (the production of
IL-5, IL-10, and IL-13) and degree III hepatic fibrosis. IL-5
and IL-13 showed the strongest association with severe hepatic
fibrosis and also increased significantly in patients who exhib-
ited increased hepatic fibrosis after 1 year without treatment.
Besides these Th2 cytokines, TGF-
 levels also increased in
the majority of the patients who exhibited increased hepatic
fibrosis after 1 year without treatment. However, TGF-
 levels
decreased in two of these patients and remained at similar
levels in two other patients, and no statistically significant dif-
ferences were detected when the first and second evaluations
were compared overall. Furthermore, TGF-
 levels did not
differ in the groups with different degrees of hepatic fibrosis.
Many variables may influence the magnitude of the immune
response in human schistosomiasis, including age, intensity of
infection, and the type of Ag used to assess immune respon-
siveness (e.g., whether the Ag is from schistosomula, adult
worms, or eggs). Moreover, increasing age is associated with an
FIG. 3. IL-10 (A) and TGF-
 (B) levels in SEA-stimulated PBMC supernatants in schistosomiasis patients with different degrees of hepatic
fibrosis. a, P  0.01; b, P  0.03 (Mann-Whitney test).
FIG. 4. IFN- (A) and TNF- (B) levels in SEA-stimulated PBMC supernatants from subjects who increased the periportal tract thickness after
one-year follow-up without treatment. a, P values determined by Wilcoxon signed rank test.













enhanced type 1 immune response (23), and heavy infections
(more than 200 EPG of feces) are associated with an enhanced
type 2 response (2). These variables did not explain the results
of the present study, since patients with degree III hepatic
fibrosis made more IL-5 and IL-13 despite the fact that their
ages were higher than the ages of the other groups and that
they had the lowest intensity of infection. Another important
point is that the increase in IL-5 and IL-13 levels in patients
with degree III liver fibrosis was only observed in SEA-stimu-
lated cultures, indicating that the type 2 immunological re-
sponse observed in these patients is directed primarily to egg
Ag.
Recent studies have pointed out an important role for IL-13
in the development of liver fibrosis (8, 9). Although IL-4 and
IL-13 share the same receptor and many biological activities,
there are functional differences between the two cytokines.
While granuloma formation was partially reduced in IL-4-de-
ficient mice, blocking IL-13 and the IL-4 receptor in these
animals almost completely eliminated granuloma development
and tissue fibrosis (9). Indeed, IL-13 stimulates collagen pro-
duction in fibroblasts and procollagen I and II mRNA expres-
sion. More recently, an IL-13 receptor 2 which blocks IL-13
function and hepatic fibrosis has been described (8). Our data,
by showing a correlation between the production of high levels
of IL-13 and the development of more severe fibrosis, suggest
that this cytokine might also play a significant role in human
schistosomiasis fibrosis. A recent study has found a protective
effect of IFN- in liver fibrosis in Sudanese S. mansoni-infected
subjects (16). The same group has also described an associa-
tion between severe hepatic fibrosis with a polymorphic allele
of the IFN- gene involved in reduced IFN- production (7).
Another recent study has also associated low IFN- production
with liver fibrosis (4). In fact, earlier studies on schistosomiasis
pathology in mice demonstrated that IFN- reduces the cellu-
larity of granulomas and downmodulates granuloma size (5).
These data are in agreement with the data from the present
study, because IFN- is the major type 1 cytokine involved in
the downmodulation of T helper type 2 cells.
In contrast to our data that showed increased levels of IL-5
and IL-13 associated with liver fibrosis, studies of schistosomi-
asis patients from Africa showed that patients with more se-
vere hepatic fibrosis had higher levels of TNF- in PBMC
supernatants (4, 16, 19). The contradictory results might be
explained by the differences in the stages of the disease eval-
uated in these two studies: while the present study evaluated
patients in the prehepatosplenic and early hepatosplenic stages
FIG. 5. IL-5 (A) and IL-13 (B) levels in SEA-stimulated PBMC supernatants from subjects in whom the periportal tract thickness had increased
at follow-up after 1 year without treatment. IL-5 and IL-13 levels increased in 50% of the patients. a, P values determined by Wilcoxon signed rank
test.
FIG. 6. IL-10 (A) and TGF-
 (B) levels in SEA-stimulated PBMC supernatants from subjects in whom the periportal tract thickness had
increased at follow-up after 1 year without treatment. IL-10 levels increased in 39% of patients and TGF-
 increased in 43% of patients. a, P values
determined by Wilcoxon signed rank test.













of schistosomiasis mansoni, these studies evaluated hepato-
splenic patients. Since the degree III hepatic fibrosis patients
are in the early hepatosplenic phase of disease evolution, it is
possible that TNF- is inducing the Symmers fibrosis that
occurs in later stages of the disease. Another possible expla-
nation for the contrasting results of these two studies is that the
African population has a high prevalence of malaria, a proto-
zoan infection that is known to cause hepatosplenomegaly and
also to induce high levels of TNF- (11). In fact, a more recent
study from one of these groups of investigators (19), evaluating
the serological response in the same population described in
the previous study, confirmed that hepatosplenic patients had
significantly higher levels of anti-Plasmodium falciparum anti-
bodies compared to levels of nonhepatosplenic patients (20).
Further studies are necessary to better clarify the cytokines
involved in advanced stages of hepatosplenic schistosomiasis
and the role of coinfections with malaria and other pathogens.
The documentation that levels of IL-10 were found to be
higher in subjects with degree III compared to degrees I and II
hepatic fibrosis was unexpected. IL-10 is a modulatory cytokine
which downregulates macrophage activation and major histo-
compatibility complex class I and class II expression and re-
duces activation of both Th1 and Th2 cells (13). Previous
studies have shown that IL-10 is important to reduce the pa-
thology of acute schistosomiasis and that the level of Il-10
decreases in patients with hepatosplenomegaly (15). Since the
patients in the present study were in the prehepatosplenic and
early stages of hepatosplenomegaly, it is possible that the doc-
umentation herein of increased levels of IL-10 in patients de-
veloping liver fibrosis may represent an attempt of this cyto-
kine to downregulate the high levels of IL-5 and IL-13.
Furthermore, in the group of patients who presented an in-
crease in hepatic fibrosis, IL-10 levels increased in seven pa-
tients but decreased in three and remained at similar levels in
three other patients, and no statistically significant changes
were demonstrated when the first and second evaluations were
compared overall. Another interesting finding from the
present study is the increased levels of TGF-
 in supernatants
from SEA-stimulated PBMC in 43% of subjects who had a
higher degree of hepatic fibrosis after 1 year without treat-
ment. Although there were no statistically significant differ-
ences between the levels of this cytokine from the first to the
second evaluation, the small increase in the TGF-
 levels
might have a biological role in the induction of hepatic fibrosis.
TGF-
 is known to be involved in fibrosis due to its ability to
induce collagen deposition (29). The increase in TGF-
 levels
during the evolution of hepatic lesions and the lack of differ-
ences in subjects with degrees I, II and III hepatic fibrosis
could be due to an intermittent induction of fibrosis.
The present study presents evidence for a role of type 2
immune response in the development of liver fibrosis in human
schistosomiasis. The expression of IL-5, IL-10, and IL-13 were
associated with degree III hepatic fibrosis and the levels of IL-5
and IL-13 increased significantly in patients who developed
more serious hepatic fibrosis over the course of the study.
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